BioCentury | Jun 23, 2020
Politics, Policy & Law

Scientists warn Trump immigration ‘pause’ will harm biopharma innovation

President Donald Trump’s decision to bar most employment-based visas through year-end could have a broad impact on the U.S. biopharma industry, which is heavily dependent on temporary and permanent immigrants to fill jobs from junior...
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

The American Association for Cancer Research elected Charles Sawyers as president; he will assume the role during AACR’s 2021 meeting, which will take place in Washington on April 9-14. Sawyers is chair of Memorial Sloan...
BioCentury | May 11, 2020
Management Tracks

Distinguished Broad professor to replace Varney as head of Roche’s gRED

Roche has again enticed an accomplished academic to lead one of its research units, this time hiring the Broad Institute’s Aviv Regev as the head of Genentech Research and Early Development. She is replacing Michael...
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin emerged from stealth Wednesday with a $15.5 million series A round and a chemogenetics platform designed to treat neurological disorders by controlling neuron excitability. 4Bio Capital and Arkin Bio Ventures led the tranched round....
BioCentury | Feb 27, 2020
Politics, Policy & Law

Plotting a scientific path to counter COVID-19

In a global online forum Tuesday night, scientific leaders from companies developing vaccines, therapies and diagnostics to address the COVID-19 outbreak discussed opportunities for collaboration, highlighted challenges, and called for sustained global initiatives to create...
BioCentury | Feb 14, 2020
Targets & Mechanisms

Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors

Rising serial entrepreneur Akiko Iwasaki aims to bring antitumor immunity to the brain by opening the brain’s lymphatics, a recently discovered system of vessels just starting to find translational uses. In 2015, a Nature paper...
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative...
BioCentury | Jan 30, 2020
Finance

Arch backs Vizgen’s RNA imaging platform with $14M series A

Arch Venture Partners is adding to its portfolio of life science tool companies by co-leading a $14 million series A for Vizgen, which is developing technology the firm thinks can overcome capacity limitations of current...
BC Extra | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

As GSK looks to expand its cell and gene therapy pipeline, the pharma has partnered with Lyell to take the modalities into solid tumors by improving T cell functionality and manufacturing. Lyell Immunopharma Inc. is...
BC Extra | Oct 8, 2019
Tools & Techniques

Nobel Prize for cell response to oxygen, a two-sided therapeutic target

Cellular responses to oxygen levels, the focus of this year's Nobel Prize in Physiology or Medicine, are the targets of both inhibiting and activating therapies in clinical development for multiple diseases. William Kaelin, Peter Ratcliffe...
Items per page:
1 - 10 of 235
BioCentury | Jun 23, 2020
Politics, Policy & Law

Scientists warn Trump immigration ‘pause’ will harm biopharma innovation

President Donald Trump’s decision to bar most employment-based visas through year-end could have a broad impact on the U.S. biopharma industry, which is heavily dependent on temporary and permanent immigrants to fill jobs from junior...
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

The American Association for Cancer Research elected Charles Sawyers as president; he will assume the role during AACR’s 2021 meeting, which will take place in Washington on April 9-14. Sawyers is chair of Memorial Sloan...
BioCentury | May 11, 2020
Management Tracks

Distinguished Broad professor to replace Varney as head of Roche’s gRED

Roche has again enticed an accomplished academic to lead one of its research units, this time hiring the Broad Institute’s Aviv Regev as the head of Genentech Research and Early Development. She is replacing Michael...
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin emerged from stealth Wednesday with a $15.5 million series A round and a chemogenetics platform designed to treat neurological disorders by controlling neuron excitability. 4Bio Capital and Arkin Bio Ventures led the tranched round....
BioCentury | Feb 27, 2020
Politics, Policy & Law

Plotting a scientific path to counter COVID-19

In a global online forum Tuesday night, scientific leaders from companies developing vaccines, therapies and diagnostics to address the COVID-19 outbreak discussed opportunities for collaboration, highlighted challenges, and called for sustained global initiatives to create...
BioCentury | Feb 14, 2020
Targets & Mechanisms

Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors

Rising serial entrepreneur Akiko Iwasaki aims to bring antitumor immunity to the brain by opening the brain’s lymphatics, a recently discovered system of vessels just starting to find translational uses. In 2015, a Nature paper...
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative...
BioCentury | Jan 30, 2020
Finance

Arch backs Vizgen’s RNA imaging platform with $14M series A

Arch Venture Partners is adding to its portfolio of life science tool companies by co-leading a $14 million series A for Vizgen, which is developing technology the firm thinks can overcome capacity limitations of current...
BC Extra | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

As GSK looks to expand its cell and gene therapy pipeline, the pharma has partnered with Lyell to take the modalities into solid tumors by improving T cell functionality and manufacturing. Lyell Immunopharma Inc. is...
BC Extra | Oct 8, 2019
Tools & Techniques

Nobel Prize for cell response to oxygen, a two-sided therapeutic target

Cellular responses to oxygen levels, the focus of this year's Nobel Prize in Physiology or Medicine, are the targets of both inhibiting and activating therapies in clinical development for multiple diseases. William Kaelin, Peter Ratcliffe...
Items per page:
1 - 10 of 235